COMMUNIQUÉS West-GlobeNewswire

Sanofi : Déclaration des transactions sur actions propres
18/09/2017
Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Ossur Hf : Transactions in relation to share buyback program
18/09/2017
Announcement from Össur hf. No. 67/2017 Reykjavík, 18 September 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Novo Nordisk A/S - Share repurchase programme
18/09/2017
Bagsværd, Denmark, 18 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Medtronic Announces FDA Approval and U.S. Launch of Next Generation Spinal Cord Stimulator for Chronic Pain Management
18/09/2017
The Intellis Platform Includes the World's Smallest Implantable Spinal Cord Stimulator and Offers Personalized Pain Relief and Advanced Activity Tracking DUBLIN - September 18, 2017 - Medtronic plc (NYSE:MDT) today [...]
AroCell AB: New application for AroCell TK 210 ELISA opens new opportunities for drug development research
18/09/2017
Uppsala September 18, 2017 PRESS RELEASE New application for AroCell TK 210 ELISA opens new opportunities for drug development research AroCell AB (publ) announces today that an abstract submitted by Kiran Kumar [...]
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis
18/09/2017
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related [...]
Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting
18/09/2017
LOS ANGELES, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations [...]
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases
18/09/2017
PRESS RELEASE Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases $40 million investment to accelerate development of Immunocore's ImmTAV® and ImmTAB® [...]
Solon Eiendom ASA : Primary insider notification
18/09/2017
(Oslo, Norway, 15 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 155,259 shares in Solon Eiendom ASA at a price of NOK 17.9561 per [...]
Cambridge Medical Robotics closes Series A fundraise with further $26 million
18/09/2017
Cambridge Medical Robotics Limited ("CMR" or the "Company") Cambridge Medical Robotics closes Series A fundraise with further $26 million Cambridge, UK, 18 September 2017 : Cambridge Medical Robotics Ltd, the private [...]
Saniona AB: Saniona reports encouraging start for tesofensine Phase 3 study
18/09/2017
PRESS RELEASE September 18, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that Saniona's partner, Medix, has recruited 150 out of the planned 372 patients in the study during the [...]
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases
18/09/2017
PRESS RELEASE Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases $40 million investment to accelerate development of Immunocore's ImmTAV® and ImmTAB® [...]
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
18/09/2017
Leuven, Belgium, 18 th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that [...]
INNATE PHARMA,: Premier semestre 2017 : Nouvelles données cliniques et enrichissement du portefeuille
18/09/2017
PREMIER SEMESTRE 2017 : NOUVELLES DONNÉES CLINIQUES ET ENRICHISSEMENT DU PORTEFEUILLE Trésorerie, équivalents de trésorerie et actifs financiers [1] s'élevant à 204,1 millions d'euros au 30 juin 2017 Importants progrès [...]
INNATE PHARMA, First half of 2017: delivering key clinical data and strengthening the pipeline
18/09/2017
first half of 2017: DELIVERING KEY CLINICAL Data and strengthening the Pipeline Cash, cash equivalents and financial assets [1] for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant [...]
Addex Makes Changes to Executive Management Team
18/09/2017
Geneva, Switzerland, 18 September 2017 - Addex Therapeutics (SIX: ADXN) announced today that Robert Lutjens, Head of Discovery will join the Executive Management Team and take over scientific leadership with support [...]
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
16/09/2017
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous [...]
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
16/09/2017
Sanofi and Regeneron Announce Positive Study Results for Dupixent ® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis - Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European [...]
Sanofi et Regeneron annoncent les résultats positifs d'une étude consacrée à Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère
16/09/2017
Sanofi et Regeneron annoncent les résultats positifs d'une étude consacrée à Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère - Présentation orale des résultats de l'étude de phase 3 [...]

Pages